GLP-1s, PCOS and the "Ozempic Baby": 10 Studies (2026)

Not a GLP-1 paper — the framework everything else is argued inside. The Endocrine Society's PCOS guideline makes weight loss first-line for patients with overweight or obesity, on the finding that reductions as small as 5 to 10% restore ovulation in a majority. ★ Its load-bearing claim for this page is that ovulation returns with the weight loss regardless of how the weight came off. That is the reasoning off-label GLP-1 use rests on, and it is also why the IVF result below is interesting: it does not fit that model.

PMID 24151290 ↗DOI 10.1210/jc.2013-2350 ↗

The first randomized signal, from 2008 and still the anchor citation: 60 women with PCOS and overweight, assigned to exenatide, metformin, or both for 24 weeks. Ovulation confirmed by mid-luteal progesterone reached 86% on the combination against 50% on exenatide alone and 24% on metformin alone, with menstrual frequency improving most on the combination. ⚠ Sixty women, 24 weeks, and a drug nobody prescribes for this now — but every later review traces back through it.

PMID 18460557 ↗DOI 10.1210/jc.2008-0115 ↗

The only trial here with a hard fertility endpoint, and the most surprising result on the page. 28 women with obesity, PCOS and prior IVF failure were given metformin or metformin plus low-dose liraglutide for 12 weeks, then a four-week washout before stimulation. Pregnancy per embryo transfer was 85.7% against 28.6%, and cumulative pregnancy over 12 months 69.2% against 35.7%. ★ The critical detail: both groups lost the same weight, about 7 kg. Whatever produced the difference, it was not weight loss. ⛔ Twenty-eight women. Treat it as the reason to run a real trial, not as a result to act on.

PMID 29703793 ↗DOI 10.1530/EJE-18-0175 ↗

A 12-week three-arm pilot from the Slovenian group: 45 women with PCOS and obesity on liraglutide 1.2 mg, roflumilast, or metformin. Liraglutide produced the most weight loss, around 3.8 kg, against very little on metformin. ⚠ Ovulation was not an endpoint, which is worth holding onto — this establishes that the drug beats metformin at removing weight in this population and says nothing directly about fertility.

PMID 26032655 ↗DOI 10.1186/s13048-015-0161-3 ↗

The first formal ranking of drug options for weight loss in PCOS, pooling randomized trials of GLP-1 drugs against orlistat, sibutramine and metformin. The GLP-1 agents came out on top for weight, BMI, waist circumference and insulin resistance. ⚠ It is heavily weighted by the same small trials listed above, so it should be read as a tidy summary of a thin literature rather than as independent confirmation of it — and it is nonetheless the citation most often used to justify prescribing.

PMID 30066361 ↗DOI 10.1111/obr.12720 ↗

The mechanistic reference, and unusually candid about its own limits. It lays out the pathways by which these drugs could affect PCOS beyond weight — insulin excess, androgen levels, the hormonal axis governing ovulation, and GLP-1 receptors expressed in ovarian tissue itself — while stating plainly that the fertility evidence at the time amounted to two randomized trials and no approval. That combination of mechanism plus honesty is why it remains the standard citation.

PMID 32442310 ↗DOI 10.1210/clinem/dgaa285 ↗

One of the few trials to test a GLP-1 against what women with PCOS are usually given rather than against placebo: 64 women with overweight randomized to a GLP-1 plus metformin or to a combined oral contraceptive plus metformin for 12 weeks. ★ The two treatments split the outcomes — the GLP-1 arm did better on weight, waist and insulin resistance, the contraceptive arm did better on testosterone. That is a genuinely useful result for choosing between them, because it says the choice depends on which problem is bothering the patient most.

PMID 37653215 ↗DOI 10.1007/s12020-023-03487-4 ↗

The most current pooled analysis, across roughly a dozen randomized trials of liraglutide, exenatide and semaglutide: about 3 kg more weight loss than comparators, BMI down about 1.5 kg/m², insulin resistance improved, and modest reductions in androgen levels. Menstrual frequency improved with high variability between studies. ⛔ Its own limitations section is the honest summary of this field — small samples, short follow-up, geographically concentrated trials, and essentially no data on sustained ovulation or live births.

PMID 39178623 ↗DOI 10.1016/j.jdiacomp.2024.108834 ↗

A review of the question nobody's trial measured: what these drugs do to the uterine lining, where implantation actually happens. GLP-1 receptors are present in endometrial tissue, and the signaling could plausibly help — less inflammation, better blood supply — or interfere with implantation. ⚠ Direction unknown in humans. It is speculative by construction, and it is the clearest articulation of why 'it worked, so it must be safe in pregnancy' does not follow.

PMID 39696822 ↗DOI 10.1111/aogs.15010 ↗

The entry with the most direct bearing on a reader's decisions. An obstetrics-aligned review that treats the surprise-pregnancy phenomenon as real but unquantified, and converts the evidence into instructions: tell patients fertility may return, discuss contraception before starting, allow at least two months between the last dose and trying to conceive, and stop immediately if a pregnancy occurs. ★ If you read one paper on this page, this is the one that changes what anyone should do.

PMID 39847778 ↗DOI 10.1097/AOG.0000000000005825 ↗